Primary open-angle glaucoma (POAG) is a chronic, progressive, usually bilateral disease of the eye with an insidious onset.
It is most often characterized by optic nerve damage, defects in the retinal fiber layer and subsequent visual field loss in the absence of underlying ocular disease or congenital abnormalities.
It is generally asymptomatic until it has caused a significant loss of visual field.
Occasionally, patients with very high intraocular pressure may complain of nonspecific headache, discomfort, intermittent blurring of vision or even halos caused by corneal edema.
Selective laser trabeculoplasty appears to be more favourable than medical therapy in the first-line treatment of patients with ocular hypertension and glaucoma, with the former associated with slower visual field (VF) progression, according to data from the Laser in Glaucoma and Ocular Hypertension Trial (LiGHT).
Omidenepag isopropyl ophthalmic solution provides an intraocular pressure-lowering benefit that is noninferior to that obtained with latanoprost eye drops in the treatment of patients with ocular hypertension or primary open-angle glaucoma, according to the results of a phase III study in Japan.
A triple fixed combination of bimatoprost 0.01%/brimonidine 0.15%/timolol 0.5% ophthalmic solution provides superior intraocular pressure (IOP)-lowering effects compared with a dual fixed combination of brimonidine 0.2%/timolol 0.5% in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT), according to the results of a phase III study.
New drug applications approved by US FDA as of 01 - 15 March 2020 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.
A novel incentive strategy which rewards patients who are compliant to their medications significantly improves adherence rates, thus providing a potential cost-effective adherence intervention, the SIGMA* study shows.
Once-daily dosing of the Rho kinase inhibitor netarsudil is not inferior to twice-daily timolol in terms of lowering intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension, while having tolerable adverse events, according to the results of the phase III ROCKET-4 trial.
A new study from the UK has suggested that patients recently diagnosed with ocular hypertension or open angle glaucoma (OAG) could derive greater benefit from undergoing selective laser trabeculoplasty (SLT) rather than being treated with intraocular pressure-reducing eye drops.
New drug applications approved by US FDA as of 01 - 15 March 2019 which includes New Molecular Entities (NMEs) and new biologics. It
does not include Tentative Approvals. Supplemental approvals may have
occurred since the original approval date.
A novel version of the Goldmann applanation tonometer (GAT) can be used as a more accurate measurement device for myopic patients after laser assisted in situ keratomileusis (LASIK) surgery in place of the current reference tonometer, according to a new study.